BALCHEM CORP (BCPC) Form 10-Q — Oct 23, 2026
Balchem's Q3 2026 net sales rose 8.6% year-over-year to $290.7 million, with net earnings up 16.0% to $46.7 million and diluted EPS of $1.46 versus $1.24 a year ago. All three segments grew, led by Animal Nutrition & Health (+11.7% sales, +82.8% segment operating earnings), and gross margin expanded to 36.4% from 35.7%. Nine-month sales reached $845.4 million (+9.3%) with net earnings of $131.6 million (+13.8%), while operating cash flow of $156.5 million funded $71.9 million of buybacks, $40 million of net debt reduction, and $30.8 million in dividends.
Key figures
- Eps
- 1.46
- Revenue
- 290658000
- Net Income
- 46728000
- Revenue Yoy
- 8.6% (Q3 2026 vs Q3 2025); 9.3% nine months
- Total Assets
- 1703572000
- Cash Position
- 66264000
- Shares Outstanding
- 31777324
- Capex 9mo
- 29605000
- Diluted eps yoy
- +17.7% ($1.46 vs $1.24, Q3)
- Gross margin q3
- 36.4% (vs 35.7%)
- Q3 2025 net sales
- 267558000
- Dividends paid 9mo
- 30773000
- Operating margin q3
- 21.5%
- Impairment charge q3
- 1915000
- Q3 2025 net earnings
- 40289000
- Effective tax rate q3
- 22.2%
- Share repurchases 9mo
- 71925000
- Operating cash flow 9mo
- 156544000
- Legal settlement gain q3
- 4000000
- Revolving loan outstanding
- 124000000
- Revolver capacity available
- 526000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.